Illumina, Inc.(NASDAQ : ILMN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-7.57%||6.47||0.7%||$452.28m|
|GILD||Gilead Sciences, Inc.||-0.76%||67.63||1.0%||$426.45m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.43%||553.24||2.7%||$408.99m|
|XLRN||Acceleron Pharma, Inc.||0.50%||172.94||5.3%||$345.45m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.07%||181.77||1.9%||$259.59m|
|XENE||Xenon Pharmaceuticals, Inc.||2.12%||33.66||0.4%||$178.19m|
|JSPR||Jasper Therapeutics, Inc.||31.57%||16.42||0.0%||$158.53m|
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.